Login    Join free Add to favorites    中文
home > news > AMSBIO : HVEM Products for Immuno-Oncology Research
Industry Updates | New Products | Supplier News | Upcoming Events | business | web
AMSBIO : HVEM Products for Immuno-Oncology Research

hits:1959     Date:11/17/17
AMSBIO has introduced a new range of Herpes Virus Entry Mediator (HVEM) products for use in immuno-oncology research. 

These new products will be of great interest to researchers studying TNFR family members such as CD137 (4-1BB), GITR, OX40, CD27, and other co-stimulatory proteins involved in B and T cell development, immune activation, and antitumor immune responses.

The AMSBIO range includes a suite of HVEM products including an HVEM/LIGHT cellular assay, recombinant LIGHT, BTLA, and HVEM proteins, HVEM and LIGHT expressing cell lines, as well as a BTLA:HVEM [Biotinylated] Inhibitor Screening Assay Kit to study these pathways.

HVEM, also known as CD270 or TNFSFR14 (Tumor Necrosis Factor Receptor Superfamily Member 14), is a cell surface receptor expressed on many immune cells, including T cells. HVEM plays a key role in herpes simplex virus infection. The interaction between HVEM and the viral protein Glycoprotein D (gD) is one of the first steps of herpes simplex virus (HSV) entry into the cell. Recently HVEM has also become an important immuno-oncology target after researchers discovered that HVEM is involved in the induction of apoptosis of tumor cells.

When HVEM interacts with a protein known as LIGHT (TNFSF14, CD258), it creates a co-stimulatory signal that activates lymphoid cells and amplifies the immune response. This means HVEM/LIGHT binding combines immune system amplification with a pro-apoptotic effect, providing a double punch against cancer, and therefore making it a particularly promising target for cancer drug discovery.

HVEM also can bind to a protein called BTLA (CD272, IgSF), which negatively regulates T-cell immune responses. Thus, HVEM can act as a molecular switch, either activating or inhibiting the immune response, depending which ligand it binds.

For further information on HVEM products, services and cell lines please visit www.amsbio.com/immunology.aspx or contact AMSBIO on 44-1235-828200/ +1-617-945-5033 / info@amsbio.com. 

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO can draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as an expert in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance organoid and spheroid type screening outcomes from a technological and cost-effective perspective.

Worldwide HQ 


AMS Biotechnology (AMSBIO) 

184 Milton Park
Abingdon 
Oxon OX14 4SE
UK
Tel:+44-1235-828200
Fax:+44-1235-820482
Email:info@amsbio.com 
Web:www.amsbio.com

North American HQ


AMSBIO LLC

1035 Cambridge Street
Cambridge
MA 02141
USA
Tel:+1.617.945.5033 
Tel:+1.800.987.0985 (toll free)
Email:info@amsbio.com
Related News>> more
advertisement

Copyright(C) 2006-2018 Bio-Equip    E-mail:web@bio-equip.cn   娌狪CP澶06040519鍙